CERS · Cerus Corp
United States · RS rating 34 · As of 2026-10-14
| Price | 2.24 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 22 / 12 / 87 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 35 / 8 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +9.6% |
| Distance from 52-week high | +31.7% |
| Market cap (USD) | $380.7M |